Investigators out of the U.K. report that post-traumatic stress disorder (PTSD) patients who used cannabis-based medicinal products (CBMPs) seem to experience improved quality of life.
Researchers cite a current paucity of clinical evidence regarding CBMPs and PTSD. To shed some light on how prescribed CBMPs might affect condition-related symptoms, as well as any associated adverse effects, investigators analyzed a series of patients from the U.K. Medical Cannabis Register. They assessed the HRQoL of PTSD patients at one, three and six months.
Of the 162 patients included in the review, just shy of 89 per cent of them were current/previous cannabis users. The median daily dosages were five milligrams of CBD and 145 mg of THC.
“Significant improvements were observed in PTSD symptoms, sleep and anxiety across all follow-up periods,” study authors write.
Though 220 adverse events were reported by 33 patients, the severity of most of these events
Read full article on The Growth Op
